drugset / Trial / NCT00679601

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

NCT00679601

Phase 2 Completed 20 enrolled Pfizer
Open-labelTreatment

Summary

The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.

Timeline

Start
2007-03-31
Primary completion
2007-05-31
Completion
2007-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavaborole Small molecule 7.5 % Topical

Indications